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Abstract. Defects of RNA metabolism have been increasingly identified in various forms of inherited neurological diseases.
Recently, abnormal RNA degradation due to mutations in human exosome subunit genes has been shown to cause complex
childhood onset neurological presentations including spinal muscular atrophy, pontocerebellar hypoplasia and myelination
deficiencies. This paper summarizes our current knowledge about the exosome in human neurological disease and provides
some important insights into potential disease mechanisms.
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INTRODUCTION
Neurodegenerative disorders are a group of debili-
tating and currently incurable disorders characterised
by progressive degeneration and death of neuronal
cells. Despite major advances in the factors that trig-
ger neurodegeneration, our understanding of neuronal
death pathways in the majority of neurodegenerative
disorders is still limited [1]. Among several poten-
tial pathways, a precise control of messenger RNA
(mRNA) processing and abundance is increasingly
being recognized as critical for gene expression and
cell survival, particularly in neurons [1].
The human genome is transcribed to produce an
extraordinary diversity of RNA, requiring complex
regulation. These regulatory events are governed by
a large number of trans-acting factors found in neu-
rons, such as RNA-binding proteins, long non-coding
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RNAs, micro-RNAs, which bind to specific cis-acting
elements or structures within mRNAs and thus control
different aspects of mRNA metabolism [1].
The degradation of mRNAs is an important reg-
ulatory step, which also controls gene expression
[2]. Interactions between many different proteins are
required for mRNA decay and these pathways are
not yet completely understood [3]. The importance of
RNA processing in neurodegeneration is highlighted
with a rapidly increasing number of human diseases
caused by mutations in proteins involved in mRNA
metabolism [4–9]. Concentration of mRNAs depends
on the balance between transcription and degradation
rates [10]. On both sides of the equilibrium, synthesis
and degradation show differences that have condi-
tioned the evolution of gene regulatory mechanisms.
Furthermore, pre- and posttranscriptional modifica-
tions can regulate both transcription and decay rates,
thereby maintaining proper mRNA homeostasis [4].
A novel mechanism of RNA-associated neurode-
generation has been suggested by the identification
of mutations in genes encoding components of the
exosome, a multi-protein complex required for rapid
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degradation of AU-rich elements (ARE) containing
RNAs [9].
mRNA degradation can be classified into two
aspects: removal of faulty mRNA species and degra-
dation of correct mRNAs to regulate protein amounts
in the cell [10]. Regular cytoplasmic mRNA decay
consists of five processes: decapping, 5′-to-3′ exonu-
cleolytic decay, deadenylation, 3′-to-5′ exonucleolytic
decay and endonucleolytic cleavage. Nonsense medi-
ated decay is the prime example of a RNA degradation
mechanism which acts as quality control for newly
synthesised mRNAs and removes aberrant mRNAs
with premature stop codons. As many mutations that
cause genetic disorders introduce premature termina-
tion codons, nonsense mediated decay is an essential
factor for most genetic disorders. Variability of non-
sense mediated decay can also influence the disease
phenotype [11]. Whereas there is a clear link between
degradation of aberrant mRNA and human disease,
other RNA degradation processes except degradation
by the exosome have not been linked to any human
genetic disorders yet.
This paper focuses on the RNA degradation by the
exosome complex and endeavours to summarise the
information on human neurological diseases caused
by deficiency of the human exosome and also provide
an overview on the potential disease mechanisms.
RNA DEGRADATION BY THE EXOSOME
Three major degradation systems are responsible for
thedestructionofthedefectivetranscripts: theexosome,
the 5′-3′ exoribonucleases, and the nonsense-mediated
mRNA decay machinery [2]. Some mammalian
mRNAs contain ARE within their 3′-untranslated
regions. Rapid degradation of ARE-containing RNAs
is performed by a multi-protein complex, the exosome.
The versatility and specificity of the exosome regu-
lates the activity and maintains the fidelity of gene
expression [12]. Nine proteins organize the “exosome
core” in a two-layered ring (Fig. 1). The central hex-
amer channel is composed by six subunits (Rrp41p/
EXOSC4, Rrp46p/EXOSC5, Rrp45p/PM/Scl-75/EX
OSC9, Rrp42p/EXOSC7, Mtr3/EXOSC6 and Rrp43p/
Oip2/EXOSC8), while the cap on the top of the
ring consists of three proteins (Rrp4/EXOSC2,
Rrp40/EXOSC3, Csl4/EXOSC1), involved in RNA
recognition and binding [13]. The exosome is essen-
tially a 3′–5′ exoribonuclease and degrades RNA
starting at the 3′ end; in addition to functioning as an
endoribonuclease in eukaryotes [14, 15]. The exosome
core has no catalytic activity, but it is provided through
the association with other proteins (RRP44/DIS3 and
RRP6/PM/Scl-100/EXOSC10 ribonucleases).
ARE recognition requires certain ARE binding pro-
teins that can interact with the exosome for recruitment,
thereby promoting the rapid degradation of RNAs
[16]. The human exosome also regulates gene expres-
sion via diverse RNA processing reactions [17]. Many
cellular RNAs that play key roles in important cel-
lular processes such as translation (rRNAs, tRNAs
and sno(Small Nucleolar)RNAs) and mRNA splicing
(sn(Small Nuclear)RNAs) are produced as precursor
molecules that are trimmed from their 3′-ends by the
human exosome [18]. The exosome may have different
roles in the different cellular compartments (nucleus,
nucleolus, cytoplasm) [19]. The exosome activity also
depends on cofactors, which show specialisation in
localisation and targeting. This organization provides
the versatility needed for the exosome to cope with
the huge variety of RNA substrates in the cell [20].
However, detailed in vivo analyses are technically chal-
lenging and many questions remain unresolved.
EXOSOMAL PROTEIN DEFICIENCY AND
HUMAN DISEASE
Autosomal recessive mutations in two core exosome
subunits, EXOSC3 and EXOSC8, have been identified
very recently in patients with complex neurological
presentations including pontocerebellar hypoplasia,
spinal motor neuron dysfunction and abnormal myeli-
nation.
EXOSC3 MUTATIONS
Mutations in EXOSC3 were reported in pon-
tocerebellar hypoplasia and spinal motor neuron
abnormalities (PCH) [9]. Many reports of patients with
EXOSC3 mutations have been published since the first
description of EXOSC3 mutations responsible for PCH
type 1 [21–26]. EXOSC3 mutations underlie about half
of the PCH1 cases [25]. A broad phenotype range and
many different mutations have been identified. The age
of onset and the severity of the clinical presentations
can be more heterogeneous than previously thought.
Spasticity can be also observed and the degree of
pontocerebellar or pure cerebellar hypoplasia is very
variable with survival in the milder forms into adult
age [26].
Different mutations, missense and frame shift/splice
site mutations have been described and it has been
J.S. Mu¨ller et al. / Exosomal Protein Deficiencies S33
Fig. 1. Schematic representation of the human exosome and its interacting complexes and the list of genes encoding the proteins involved in
these complexes.
assumed that the mutations are either null or hypo-
morphic alleles [9]. Genotype-phenotype correlations
indicate that one missense mutation p.Asp132Ala
is associated with milder phenotype if present in
homozygous state [25]. The patients have a longer life
expectancy and preservation of the pons compared to
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PCH1 patients with otherEXOSC3mutations. Notably,
cerebellar cysts were present in three out of four
patients compound heterozygous for p.Asp132Ala and
another mutation; these patients also suffered from
a more severe disease phenotype than the patients
homozygous for p.Asp132Ala [25]. Another EXOSC3
mutation, p.Val80Phe, is also associated with a milder
phenotype of early onset spasticity, mild intellectual
disability, distal amyotrophy, and cerebellar atrophy
in a patient of Bangladeshi origin [23]. However,
a founder mutation p.Gly31Ala in the Czech Roma
population cause a severe form and fatal before 6
months of age [24]. Recently, a novel homozygous
EXOSC3 mutation, p.Gly191Cys, was reported to
cause autosomal recessive hereditary spastic paraple-
gia in a consanguineous family of Arab origin [26].
Patients with this mutation survived until adulthood.
No patients with complete loss of EXOSC3 (i.e. two
null mutations) have been reported yet; a complete
loss of EXOSC3 is likely to be lethal. The expres-
sion of EXOSC3 protein was not assessed in patient
material (cells or tissue) by western blot. It is unclear
whether the mutations indeed lead to a reduction of
protein amount and if there is any difference among
the individual missense mutations.
Knockdown of Exosc3 in zebrafish embryos by
antisense morpholino oligonucleotides resulted in
embryos of reduced body length, curved spine and a
small brain [9]. The embryos displayed poor motility
and died around 3 days post fertilization. A shrunken or
collapsed hindbrain was detected in exosc3 morphants;
whole-mount in situ hybridization further showed a
lack of expression of pvalb7, a specific marker for dif-
ferentiated cerebellar Purkinje neurons. The zebrafish
data indicate that normal function of the EXOSC3
component is essential for the survival of cerebellar
and spinal motor neurons. Although a large number of
patients with EXOSC3 mutations have been described
by several groups, very little functional analysis has
been performed yet to understand the consequences of
EXOSC3 mutations.
EXOSC8 MUTATIONS
Our group identified mutations in another exosome
component, EXOSC8, in children with hypomyeli-
nation, spinal muscular atrophy and cerebellar
hypoplasia [27]. Two homozygous missense muta-
tions, p.Ser272Thr and p.Ala2Val, were identified
in patients from three independent families, two
of Hungarian Roma origin and one consanguineous
Arab–Palestinian family, respectively. These are to
date the only two EXOSC8 mutations that have
been reported. EXOSC8 mutations seem less fre-
quent than EXOSC3 mutations. One of the mutations,
p.Ser272Thr, could be a founder mutation in the Hun-
garian Roma population. The other mutation was
identified in a Palestinian family. No null mutations
have been described so far. The patients have slightly
different clinical phenotypes but genotype-phenotype
correlation is difficult given the low number of patients
and mutations.
We have shown by Western Blot analysis of patient
myoblasts and fibroblasts that both EXOSC8 muta-
tions lead to a reduction of EXOSC8 protein amount
in patient cells, indicating that the missense mutations
act as hypomorphic mutations [27].
There is significant overlap of the clinical phenotype
between EXOSC3 and EXOSC8 deficient patients but
clinical phenotypes are not identical although the two
proteins are thought to function together in the same
complex. It might be that the missense mutations alter
the RNA binding abilities of the exosome and different
mutations change binding affinities for a different sub-
set of RNAs. We showed that EXOSC8 is an essential
protein of the exosome core, as its depletion caused
a severe growth defect in yeast. Experimental down-
regulation of EXOSC8 in human oligodendroglia cells
and in zebrafish induced a specific increase in the ARE
mRNAs encoding myelin proteins. This imbalanced
supply of the different myelin proteins caused a dis-
ruption of myelin formation and supports the clinical
presentation. Downregulation of the EXOSC8 paralog
in zebrafish by antisense morpholino oligonucleotide
injection resulted in morphants with abnormal head
and tail appearance and impaired movement. Exam-
ination of the brain and nervous system in exosc8
morphants revealed loss of myelination of axons and
a disrupted structure of cranial motor neurons in the
morphants with the most severe phenotype. Like pre-
viously shown for EXOSC3, the absence of EXOSC8
in zebrafish embryos recapitulated many of the disease
characteristics observed in patients.
EXOSOME – ASSOCIATED COMPLEXES
Exosome activity in the nucleus and in the cytosol
is assisted by different cofactors and associated pro-
teins; these cofactors determine the specificity of the
exosome and are important for distinguishing between
RNA molecules that need to be degraded and oth-
ers that need to be processed. RNA substrates are
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guided to the exosome with the help of the two
associated complexes, the nuclear TRAMP complex
(Trf4–Air2–Mtr4 polyadenylation complex) or the
cytoplasmic Ski (superkiller) complex (Fig. 1) [28,
29]. The helicase components of these two complexes,
Mtr4 and Ski2, are important exosome regulators. Ski2
associates with Ski3 and Ski8 to form the so-called
Ski complex; the role of the Ski complex is exosome-
mediated cytoplasmic mRNA degradation and mRNA
surveillance [29]. The best characterized cofactor of
the nuclear exosome in yeast is Trf4p/5p-Air1p/2p-
Mtr4p polyadenylation (TRAMP) complex [30]. The
TRAMP complex targets nuclear RNA (incorrectly
processed RNAs, rRNAs tRNAs, as well as non-coding
RNAs) to the exosome for degradation or processing.
In mammals, two distinct nuclear exosome cofac-
tors have so far been characterized, which are the
nucleolar- localized hTRAMP complex [31] and
the nucleoplasm-specific Nuclear Exosome Targeting
(NEXT) complex [32]. hMTR4 is shared between
the two complexes. The proteins RBM7, hMTR4 and
ZCCHC8, form the NEXT complex [33], which is
specifically involved in the exosomal degradation of
PROMoter uPstream Transcripts (PROMPTs) [34].
These sequences are produced only upstream of the
promoters of active protein coding genes and are
rapidly turned over by the exosome complex [34].
Although the general function of PROMPTs remains
unknown, it seems they might be involved in fine tuning
of gene expression [34, 35].
The Ski complex is an obligatory co-factor of the
RNA exosome in the cytoplasm in yeast; the com-
ponents of the human SKI complex have not yet
been well characterised. Mutations in the SKI com-
plex components SKIV2L or TTC37 (thought to be
the human paralogs of Ski2 and Ski3, respectively)
cause a rare genetic condition named trichohepatoen-
teric syndrome; SKIV2L and TTC37 mutations have
recently been reviewed in Fabre et al. [29]. No muta-
tions in TRAMP or NEXT complex components have
been identified yet in human disease.
CONCLUSIONS
Early-onset and progressive neurological presenta-
tions affecting motor neurons, cerebellar Purkinje cells
and oligodendroglia are typical for mutations in exoso-
mal proteins and highlight the importance of exosome
function in developing neurons. Despite the complex
and central role of the exosome and its associated com-
plexes in RNA metabolism in all cell types it is so
far not known why and how only neuronal cells are
affected by exosomal protein deficiency. The exosome
may be also important for degradation of various pop-
ulations of non-coding RNA [36, 37]. Accumulation
of certain non-coding RNAs in addition to mRNAs
might contribute to disease mechanism. Non-coding
RNA expression is even more cell type specific than
mRNA expression, which could explain why some
neuronal cell types are more affected by exosome
mutations. Identifying the exact biochemical pathways
of RNA metabolism alterations due to different types
of exosome dysfunction may explain why mutations
in separate components of the exosome cause differ-
ent disease presentations, which is surprising given the
fact that exosomal components function together in a
single protein complex. Other genetic forms of pon-
tocerebellar hypoplasias are also caused by mutations
in RNA processing molecules, such as tRNA splicing
endonuclease subunit genes (PCH2, PCH4, PCH5) or
mitochondrial tRNA synthetases (PCH6) [8]. Splic-
ing of the pre-mRNAs by the spliceosome depends
on small nuclear ribonucleoproteins (snRNPs), which
require Spinal Motor Neuron 1 (SMN1) protein for
their assembly and defect of SMN1 results in spinal
muscular atrophy (SMA), a leading cause of infantile
mortality [6]. The fact that defects in RNA processing
and degradation can cause severe neurological disor-
ders emphasises the role of the RNA metabolism for
the development and maintenance of cells in the ner-
vous system. It remains to be determined why neuronal
cells are more vulnerable to changes in RNA levels than
other cell types.
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